Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia

Journal of Nephrology

Volumn 26, Issue 6, 2013, Pages 1114-1121

  Locatelli, Francesco ^a   Mandolfo, Salvatore ^b   Adorati, Massimo Menegato ^c   Villa, Giuseppe ^d   Tarchini, Renzo ^e   Pizzarelli, Francesco ^f   Conte, Ferruccio ^g   Guastoni, Carlo ^h   Ricciardi, Biagio ⁱ   Crotta, Alessandro ^j  

^a A MANZONI HOSPITAL   (Italy)

^b Lodi Hospital   (Italy)

^c S Antonio Hospital   (Italy)

^d IRCCS   (Italy)

^e CARLO POMA HOSPITAL   (Italy)

^f SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^g Uboldo Hospital   (Italy)

^h Legnano Hospital   (Italy)

ⁱ Fogliani Hospital   (Italy)

^j ROCHE MILANO RICERCHE   (Italy)

more..

Author keywords

Anemia; Cera; Chronic renal anemia; Hemodialysis; Hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN A; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANEMIA; ARTERIOVENOUS FISTULA THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; BLOOD TRANSFUSION; BRONCHITIS; CHRONIC KIDNEY DISEASE; COUGHING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; INTENTION TO TREAT ANALYSIS; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; ERYTHROCYTE TRANSFUSION; ITALY; METABOLISM; MIDDLE AGED; REFERENCE VALUE; UTILIZATION;

AGED; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBIN A; HUMANS; ITALY; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REFERENCE VALUES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84889680401     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000251     Document Type: Article

References (21)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162(12):1401-1408.
2. Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens. 2002;11(3): 337-341.
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-1510.
4. Evans RW, Rader B, Manninen DL; Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA. 1990;263(6):825-830.
5. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-619.
6. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19(1): 121-132.
7. Locatelli F, Del Vecchio L, Pozzoni P. Clinical benefits of slowing the progression of renal failure. Kidney Int Suppl. 2005;68(99):S152-S156.
8. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992-1000.
9. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-1191.
10. Eckardt KU, Kim J, Kronenberg F, et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol. 2010;21(10):1765-1775.
11. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R; ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24(2): 348-354.
12. Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother. 2012;13(4):495-503.
13. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81(1): 63-69.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice, E6(r1). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Accessed June 25, 2012.
15. Roche Pharma AG. Mircera solution for injection in pre-filled syringe. Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000739/WC500033672. pdf. Accessed April 26, 2012.
16. Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73(2):94-103.
17. Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26(5):1083-1089.
18. Locatelli F, Villa G, de Francisco AL, et al. BA16286 Study Investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: Once monthly administration. Curr Med Res Opin. 2007;23(5):969-979.
19. Levin NW, Fishbane S, Cañedo FV, et al. MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet. 2007;370(9596):1415-1421.
20. Carrera F, Lok CE, de Francisco A, et al. PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycolepoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant. 2010;25(12):4009-4017.
21. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol. 1992;2(9):1405-1416.